Organization | Leo W. Jenkins Cancer Center

Leo W. Jenkins Cancer Center Report issue

Academic/Hospital Phase 2

Founded: Greenville NC United States (2005)

Organization Overview

First Clinical Trial

2006

NCT00868114

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2014

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 2 Trials (10)

aldesleukin (Proleukin) (1 trial)

autologous melanoma lysate/klh-pulsed autologous dendritic cell vaccine (1 trial)

bevacizumab (avastin) (1 trial)

carboplatin (paraplatin) (3 trials)

cisplatin (platinol) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

doxorubicin (Doxil) (1 trial)

gemcitabine (gemzar) (1 trial)

irinotecan (Camptosar) (1 trial)

paclitaxel (taxol) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lung Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 6
# of Trial APIs: 10